Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (824)	12/5/2001 4:35:39 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 834

Actelion Tracleer distribution network bypasses traditional wholesale and retail outlets. Monthly supplies of pulmonary hypertension agent will be shipped direct to patients, along with reminders to comply with liver monitoring and pregnancy screening recommendations. Drug will cost approximately $28,500 per year. Actelion hopes to have 3,000 patients on therapy by end of 2002. --From Pink Sheet FWIW, if I were the mnfr I would approach this drug with the intent of MAXIMIZING patient compliance with liver testing. Wilder